By Natasha Eldridge, Director of RESI Conference Series, LSN
Life Science Nation (LSN) is proud to announce that McDermott Will & Emery will serve as a title sponsor for the inaugural RESI NYC on November 15, 2017. McDermott joins RESI NYC title sponsors WuXi AppTec, a leading global pharmaceutical, biotechnology and medical device open-access capability and technology platform, and Johnson and Johnson Innovation (JLABS), which provides state of the art laboratories, core research facilities, resources and connections to early stage life science innovators.
“We are proud to have been a sponsor of RESI since its inception and are particularly excited to join Wuxi AppTec and JLABS as title sponsors of the inaugural RESI in New York, a burgeoning region for life sciences,” said Byron Kalogerou, founder and chair of the firm’s Life Sciences Industry Group. “We are continually impressed at the global convening power of RESI in its ability to connect early stage CEOs with the full spectrum of funding sources from VCs, corporate VCs, family offices and sovereign funds to venture philanthropies. We are excited that many of our early stage clients in our Life Sciences Entrepreneurs Acceleration Program (“LEAP”) will have an opportunity to participate as well.”
“We look forward to sharing our legal insights with RESI attendees in New York in November, and at the September conference in Boston, where we will convene a panel on negotiating term sheets to be led by McDermott Will & Emery attorneys Brian Bunn and Jonathan Ursprung,” said Kalogerou. “Our new partner, Linda Ji, will moderate the RESI panel on Chinese Investment.”
McDermott Will & Emery offers deep experience in health care and life sciences, and provides a continuum of legal services that will meet the needs of life sciences companies at every stage of development. The firm’s Life Sciences Industry Group is comprised of 135 professionals, 60 with advanced degrees and many others with government and industry experience across 19 offices around the world. Learn more here.
Next Phase Newsletter 
Leave a comment